NMRA Deadline: NMRA Investors with Losses in Excess of $100K Have Opportunity to Lead Neumora Therapeutics, Inc. Securities Lawsuit First Filed by The Firm

Core Viewpoint - Rosen Law Firm is reminding purchasers of Neumora Therapeutics, Inc. common stock about the April 7, 2025 deadline to become a lead plaintiff in a securities class action related to the company's September 2023 IPO [1]. Group 1: Class Action Details - Investors who purchased Neumora common stock may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court by April 7, 2025, to serve as lead plaintiff, representing other class members [3]. - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [6]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements in recovering hundreds of millions for investors [4]. - The firm has been recognized for its performance in securities class action settlements, including a notable settlement against a Chinese company and being ranked highly by ISS Securities Class Action Services [4]. Group 3: Case Specifics - The lawsuit alleges that Neumora's Offering Documents contained false or misleading statements regarding the Phase Three Program and the adequacy of data from Phase Two Trials, which misled investors about the company's prospects [5].